Prescription medication · Prostaglandin Analog (Ophthalmic)
travoprost
Also sold as Travatan Z. Travoprost eye drops are used to lower high pressure inside your eye.
Data updated 2026-05-15
- 8,423
- FDA reportsLightly reported
- 85% less
- Generic vs brandHuge savings
- $94.31
- Brand price (NADAC)
What the data shows
travoprost (Travatan Z) is a prescription Prostaglandin Analog (Ophthalmic), reported less often than most tracked drugs (8,423 FDA reports), whose generic runs roughly half the brand price or less (85% less).
Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.
travoprost (Travatan Z) is a prescription Prostaglandin Analog (Ophthalmic). Travoprost eye drops are used to lower high pressure inside your eye.
Travoprost eye drops help lower pressure in the eye. It is used to treat glaucoma and high eye pressure.
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Brand Price
$94.31/unit
Generic Price
$13.81/unit
Generic Savings
85%
Generic Available
Yes (7 manufacturers)
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
What it does
Travoprost eye drops are used to lower high pressure inside your eye.
Common side effects
Redness of the eye (30-50% of users)
Key warnings
Travoprost can cause your iris (the colored part of your eye), eyelid, and eyelashes to darken.
The sections below are summarized in plain English from travoprost's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Travoprost is like a natural substance in your body. It works by helping fluid drain better from inside your eye. This lowers the pressure in your eye.
Side Effects (from patient reports)
Based on 8,423 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for travoprost, by number of reports
- Treatment Failure
Treatment Failure
1,945 reports
- Ocular Hyperaemia 490
Ocular Hyperaemia
490 reports
- Eye Irritation 478
Eye Irritation
478 reports
- Eye Pain 336
Eye Pain
336 reports
- Intraocular Pressure Increased 295
Intraocular Pressure Increased
295 reports
- Hypersensitivity 269
Hypersensitivity
269 reports
- Fatigue 261
Fatigue
261 reports
- Glaucoma 255
Glaucoma
255 reports
- Vision Blurred 227
Vision Blurred
227 reports
- Dizziness 226
Dizziness
226 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for travoprost each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where travoprost sits
travoprost has more FDA adverse-event reports than 35% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is travoprost; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 8,423 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2004–2025.
Total Reports
8,423
Reports Mentioning Death
323
3.8% of reports — not proof of cause
Hospitalization Reports
1,103
Top Indication
Product Used For Unknown Indication
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 1 | TREATMENT FAILURE | 1,945 |
| 3 | OCULAR HYPERAEMIA | 490 |
| 4 | EYE IRRITATION | 478 |
| 5 | EYE PAIN | 336 |
| 6 | INTRAOCULAR PRESSURE INCREASED | 295 |
| 7 | HYPERSENSITIVITY | 269 |
| 8 | FATIGUE | 261 |
| 9 | GLAUCOMA | 255 |
| 10 | VISION BLURRED | 227 |
| 11 | DIZZINESS | 226 |
| 12 | HEADACHE | 226 |
| 13 | VISUAL IMPAIRMENT | 215 |
| 14 | DEATH | 204 |
| 15 | DYSPNOEA | 197 |
| 16 | FALL | 186 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
Travoprost can cause your iris (the colored part of your eye), eyelid, and eyelashes to darken. The iris change may be permanent. Eyelash changes, like increased length and thickness, are usually reversible when you stop using the drops. Use caution if you have inflammation inside your eye, as this medicine may worsen it.
Common Questions
Can travoprost change my eye color?
Can I use travoprost with my other eye drops?
What if I wear contact lenses?
How long does it take for travoprost to work?
What should I do if my eyes become irritated?
Can travoprost make my eyelashes grow longer?
Is it okay to drive after using these eye drops?
What ingredients are in Travatan Z?
Can I use travoprost if I am breastfeeding?
What do I do if I accidentally use too many drops?
What are the common side effects of travoprost?
What drug class is travoprost?
Is there a generic version of travoprost?
What pregnancy or breastfeeding source fields are listed for travoprost?
Related Medications in Prostaglandin Analog (Ophthalmic)
Other drugs grouped near travoprost - same-class peers and common alternatives.
aflibercept
Eylea
AHZANTIVE is a medicine used to treat certain eye problems.
Compare with travoprost →
artificial tears
Refresh, Systane
Artificial tears are eye drops that lubricate your eyes.
Compare with travoprost →
bevacizumab (ophthalmic)
Avastin
Avastin is a medicine that blocks a protein called vascular endothelial growth factor (VEGF).
Compare with travoprost →
bimatoprost
Lumigan
Bimatoprost eye drops help lower pressure in the eye.
Compare with travoprost →
brimonidine ophthalmic
Alphagan P
Alphagan P eye drops help lower pressure in the eye.
Compare with travoprost →
Compare beyond drug class
Nationwide peers by FAERS volume & death-report share
Two PlainMeds-derived comparison paths for travoprost: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.
Similar FAERS report volume
Nearest drugs by total FAERS reports. This record: 8,423.
Similar death-report share
Nearest drugs by FAERS death-report share. This record: 3.83%.
- methylphenidate Δ 0.00 pts · 27,931 reports · CNS Stimulant 3.83%death share
- mefenamic acid Δ 0.02 pts · 2,104 reports · Nonsteroidal Anti-Inflammatory Drug (NSAID) 3.85%death share
- apremilast Δ 0.03 pts · 143,174 reports · PDE4 Inhibitor 3.81%death share
- oxaprozin Δ 0.07 pts · 2,050 reports · Nonsteroidal Anti-Inflammatory Drug (NSAID) 3.90%death share
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on travoprost
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for travoprost
The FDA label for travoprost (sold under brand names such as Travatan Z) classifies it as a prescription-only medication in the Prostaglandin Analog (Ophthalmic) class. Travoprost eye drops are used to lower high pressure inside your eye. Official labeling lists 1 commonly reported side effect, including Redness of the eye (30-50% of users).
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 8,423 voluntary reports. Interaction data is drawn directly from FDA-approved prescribing information. NADAC pricing from CMS shows a generic unit cost of $13.81 versus $94.31 for the brand - a 85% generic savings.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: September 21, 2023
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages